Full-Time

Product Designer

Avelios Medical

Avelios Medical

201-500 employees

Neuromorphic processors for brain-like sensing

No salary listed

Munich, Germany

In Person

Occasional travel to hospitals for on-site research is required.

Bachelor's

Category
UI/UX & Design (1)
Required Skills
Claude
Usability Testing/Engineering
Figma
Product Design
Storybook

Get referred to Avelios Medical

See people who can refer or advise you

Requirements
  • A degree in design, human–computer interaction, communication sciences, information design, or a comparable field is required.
  • At least 2 years of product design experience in a complex business-to-business software environment, including hands-on work on real-world digital applications beyond websites, is required.
  • Proficiency with modern design tools, especially Figma, high-fidelity prototyping, user experience principles, and testing methods is required.
  • Experience working with and contributing to tokenized design systems is required.
  • The candidate must collaborate effectively with engineering, engage in trade-off discussions, and clearly communicate how design decisions affect usability, performance, and outcomes.
  • An understanding of accessibility standards and their practical application in digital interfaces is required.
  • The candidate must be a systems thinker with a solution-oriented mindset who can operate in ambiguity and drive clarity, execution, and continuous improvement in a fast-paced environment.
  • Fluency in German and English is required.
Responsibilities
  • Design user-centric solutions that balance user needs, medical requirements, technical feasibility, and business goals.
  • Create Figma prototypes, intuitive user flows, and high-fidelity screens to communicate, validate, and refine ideas.
  • Collaborate with product managers, engineers, and medical professionals to iterate and deliver high-quality software experiences.
  • Work with engineering on trade-off discussions and contribute to design systems and Storybook to ensure consistency, scalability, and feasibility.
  • Formulate hypotheses and design user interviews, usability tests, and occasional on-site research to generate actionable insights and validate design decisions.
  • Own meaningful product challenges, shape critical decisions, and create tangible impact in a high-growth environment.
Desired Qualifications
  • Experience in the healthcare industry is a plus.
  • Familiarity with artificial-intelligence-assisted prototyping tools such as Claude, Cursor, or V0 is a plus.

Avelios Medical makes ultra-efficient neuromorphic processors that imitate how the brain processes information. Their devices use analog-mixed signal circuits to recreate spiking neurons and synapses, allowing sensor data to be processed faster and with much less energy than traditional computer chips. The hardware-based approach is different from software-focused AI by building brain-like processing directly into the processor. This lets businesses access and analyze sensor data more quickly while consuming less power, with goals that include enabling AI-powered healthcare tools and other healthcare-digital workflows.

Company Size

201-500

Company Stage

Series A

Total Funding

$37.7M

Headquarters

Munich, Germany

Founded

2020

Get referred to Avelios Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Avelios reports 70 clinics using its platform, signaling commercial traction today.
  • Remy Lazarovici joined as CCO in 2026, strengthening enterprise sales execution.
  • SAP partnership access and Fresenius backing accelerate rollouts across European hospital networks.

What critics are saying

  • SAP may pivot after 2030 IS-H exits, weakening Avelios's distribution advantage.
  • Dedalus, CGM, and Oracle Health already own hospital IT relationships across Germany.
  • Avelios's 220-person team must scale deliveries fast; missed implementations stall enterprise rollouts.

What makes Avelios Medical unique

  • SAP and Fresenius invested on 2026-05-06, validating Avelios's hospital platform.
  • Avelios targets IS-H replacement with a cloud-native, modular KIS built in Europe.
  • Thoraxklinik Heidelberg selected Avelios in 2026, showing credibility in live university-hospital deployments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Stock Options

Meal Benefits

Commuter Benefits

Employee Discounts

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-5%
AInvest Fintech Inc.
May 6th, 2026
Fresenius and SAP invest in Avelios Medical's AI-native hospital information systems

Fresenius and SAP have invested in Avelios Medical, a health technology company developing AI-native hospital information systems for European healthcare. The partnership aims to accelerate healthcare digitisation through a data-driven platform integrating medical and business processes across hospital systems. Avelios Medical's platform is designed to reduce administrative burdens, enhance data utilisation for research and treatment, and improve operational efficiency. The collaboration addresses fragmented IT landscapes in hospitals by combining Avelios' AI-native systems with SAP's enterprise software expertise. The investment reflects growing interest in digital health solutions prioritising data sovereignty and sustainability. Industry observers note the partnership's potential to reshape healthcare IT by promoting interoperability and leveraging AI in clinical and administrative workflows across the European healthcare sector.

Hogan Lovells
May 6th, 2026
Hogan Lovells advises Avelios on a strategic investment by Fresenius.

Hogan Lovells advises Avelios on a strategic investment by Fresenius. Press releases | 06 May 2026 Munich - Global law firm Hogan Lovells has advised Avelios Medical GmbH on a strategic investment by Fresenius. Avelios defines the fundament for the data-driven hospital of the future with its AI-native digital hospital information system as central platform. Developed in line with clinical requirements, the software reduces the burden of documentation and facilitates clinical workflows, thereby enabling consistently interoperability and clinical intelligence for the first time. The partnership with Europe's largest private hospital operator, Fresenius, will support the reliable scaling of the Avelios platform across the entire scope of healthcare. Fresenius's extensive practical experience in healthcare - covering proven processes and real-world clinical requirements - will be integrated into the technology partnership with SAP, which was already established in February this year. Avelios defines the foundation for automation and the productive use of AI in everyday clinical practice, thereby forming the platform's core clinical architecture. Hogan Lovells provided comprehensive legal advice to Avelios and supported the company throughout the transaction. The team was led by corporate partner Peter Huber with support from associates Dr. Patrick Waldecker, Artem Vesdenetski and Shervin Mir Marashi. Additional advise was provided by partner Dr. Christoph Wünschmann and senior associate Benedikt Weiss on all antitrust matters.

Stock-World
Feb 28th, 2026
SAP invests in Avelios Medical and launches $11.3B share buyback programme amid share price decline

SAP has made a strategic investment in Munich-based HealthTech company Avelios Medical, whilst launching a share buyback programme worth up to €10 billion to restore investor confidence following significant share price losses. The investment is linked to SAP's withdrawal from the traditional hospital information systems market by 2030. SAP's shares have fallen approximately 37% from their June 2025 peak, trading at €170.32, with a 15% decline since the start of 2026. The drop followed disappointing cloud order backlog figures in Q4 2025, despite solid overall performance including 26% cloud revenue growth and free cash flow exceeding €8 billion. The company is implementing countermeasures, including the buyback programme running until end-2027, a proposed €2.50 dividend per share, and focusing on AI integration, with two-thirds of Q4 cloud orders containing AI components.

HTGF (High-Tech Gründerfonds)
Feb 26th, 2026
SAP invests in Avelios Medical

SAP invests in Avelios Medical. News article. SAP, one of our long-standing limited partners, makes a strategic investment in our portfolio company Avelios Medical, a company that is reshaping hospital IT and clinical workflows. Together, Avelios and SAP offer an open, AI-native and sovereign platform, developed in Europe and designed for enterprise-scale hospital rollouts. SAP's commitment reflects conviction in a company that HTGF has backed at the earliest stage. At HTGF, we sit at the intersection of bold founders and industry-defining LPs. When the two sides connect that's the HTGF flywheel working. What makes Avelios particularly compelling is its timing. The IS-H transformation is reshaping the clinical IT market, and hospitals facing fundamental IT realignments need orientation. Avelios is exactly that. The company offers a platform that integrates clinical workflows, patient data, and administrative processes - built on a structured, semantically consistent data model that enables interoperability and clinical intelligence at enterprise scale. Daniela bach principal. I am your contact. More news. 26 February 2026 Europe builds again as fusion moves from lab to grid: proxima fusion on its way to strengthening european energy sovereignty. Clee Medical secures seed financing to advance real-time brain imaging for neurosurgery. 25 February 2026 17 February 2026 Growth turbo for the heating transition: nuuenergy raises €4.3 million to revolutionise the heat-pump market with craft expertise. 11 February 2026 INLEAP photonics secures pre-seed funding to develop laser-based counter-drone system for defence and critical infrastructure. 2 February 2026

e-health-com GmbH
Feb 25th, 2026
SAP invests in Avelios to build AI-native healthcare platform and replace IS-H system

Avelios Medical, a provider of AI-native hospital information systems, has received a strategic investment from SAP to jointly develop the healthcare platform of the future. The investment comes as hospitals navigate the IS-H transformation in the clinical information systems market. The partnership combines Avelios's clinical process expertise with SAP's enterprise integration capabilities to create an open, AI-native platform developed in Europe. Avelios will use the funding to scale team capacity, focusing on product development and delivery structures for enterprise-scale rollouts. The solution features a cloud-native, modular architecture with structured data models enabling AI automation and intelligent orchestration of clinical and operational processes. SAP's investment provides access to its global ecosystem of implementation partners and decades of enterprise transformation expertise, offering hospitals investment security during fundamental IT realignments.